[HTML][HTML] Comparison of ifosfamide, carboplatin and etoposide versus etoposide, steroid, and cytarabine cisplatin as salvage chemotherapy in patients with refractory …
Background: Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50% of patients.
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or …
V Mehrzad, F Ashrafi, AR Farrashi, R Pourmarjani… - 2017 - agris.fao.org
Background: Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50% of patients.
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
[PDF][PDF] Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with …
V Mehrzad, F Ashrafi, AR Farrashi, M Dehghani - chemotherapy (CT) - academia.edu
Abstract Background: Refractory or relapsed Hodgkin's disease (HD) occurs in 10‑50% of
patients. The treatment of choice for these patients is high‑dose chemotherapy (HDCT) and …
patients. The treatment of choice for these patients is high‑dose chemotherapy (HDCT) and …
Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or …
V Mehrzad, F Ashrafi, AR Farrashi… - Advanced Biomedical …, 2017 - europepmc.org
Background Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50% of patients.
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or …
V Mehrzad, F Ashrafi, AR Farrashi… - Advanced biomedical …, 2017 - eprints.mui.ac.ir
BACKGROUND: Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50 of patients.
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or …
V Mehrzad, F Ashrafi, A Farrashi… - Advanced Biomedical …, 2017 - go.gale.com
Background: Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50% of patients.
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or …
V Mehrzad, F Ashrafi, AR Farrashi… - Advanced …, 2017 - advbiores.mui.ac.ir
Background: Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50% of patients.
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or …
V Mehrzad, F Ashrafi, AR Farrashi… - Advanced …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50% of patients.
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or …
V Mehrzad, F Ashrafi, A Farrashi… - Advanced …, 2017 - search.proquest.com
Background: Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50% of patients.
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
[HTML][HTML] Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with …
V Mehrzad, F Ashrafi, AR Farrashi… - Advanced Biomedical …, 2017 - ncbi.nlm.nih.gov
Background: Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50% of patients.
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …